Anna Aspesi*, Chiara Borsotti and Antonia Follenzi* Pages 327 - 335 ( 9 )
Diamond Blackfan Anemia (DBA) is an inherited erythroid aplasia with onset in childhood. Patients carry heterozygous mutations in one of 19 Ribosomal Protein (RP) genes, that lead to defective ribosome biogenesis and function. Standard treatments include steroids or blood transfusions but the only definitive cure is allogeneic Hematopoietic Stem Cell Transplantation (HSCT). Although advances in HSCT have greatly improved the success rate over the last years, the risk of adverse events and mortality is still significant.
Clinical trials employing gene therapy are now in progress for a variety of monogenic diseases and the development of innovative stem cell-based strategies may open new alternatives for DBA treatment as well. In this review, we summarize the most recent progress toward the implementation of new therapeutic approaches for this disorder. We present different DNA- and RNA-based technologies as well as new candidate pharmacological treatments and discuss their relevance and potential applicability for the cure of DBA.
Bone marrow failure syndrome, Diamond blackfan anemia, Gene editing, Gene therapy, Ribosomal protein, Ribosomopathy.
Department of Health Sciences, Università del Piemonte Orientale, Novara, Department of Health Sciences, Università del Piemonte Orientale, Novara, Department of Health Sciences, Università del Piemonte Orientale, Novara